{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:18:55Z","timestamp":1785352735273,"version":"3.55.0"},"reference-count":19,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:00:00Z","timestamp":1714176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Friends of Cancer Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Circulating tumor DNA (ctDNA) holds promise as a biomarker for predicting clinical responses to therapy in solid tumors, and multiple ctDNA assays are in development. However, the heterogeneity in ctDNA levels prior to treatment (baseline) across different cancer types and stages and across ctDNA assays has not been widely studied. Friends of Cancer Research formed a collaboration across multiple commercial ctDNA assay developers to assess baseline ctDNA levels across five cancer types in early- and late-stage disease. This retrospective study included eight commercial ctDNA assay developers providing summary-level de-identified data for patients with non-small cell lung cancer (NSCLC), bladder, breast, prostate, and head and neck squamous cell carcinoma following a common analysis protocol. Baseline ctDNA levels across late-stage cancer types were similarly detected, highlighting the potential use of ctDNA as a biomarker in these cancer types. Variability was observed in ctDNA levels across assays in early-stage NSCLC, indicative of the contribution of assay analytical performance and methodology on variability. We identified key data elements, including assay characteristics and clinicopathological metadata, that need to be standardized for future meta-analyses across multiple assays. This work facilitates evidence generation opportunities to support the use of ctDNA as a biomarker for clinical response.<\/jats:p>","DOI":"10.3390\/diagnostics14090912","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T11:39:42Z","timestamp":1714649982000},"page":"912","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Advancing Evidence Generation for Circulating Tumor DNA: Lessons Learned from A Multi-Assay Study of Baseline Circulating Tumor DNA Levels across Cancer Types and Stages"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9239-7153","authenticated-orcid":false,"given":"Brittany A.","family":"McKelvey","sequence":"first","affiliation":[{"name":"Friends of Cancer Research, Washington, DC 20036, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0177-2024","authenticated-orcid":false,"given":"Hillary S.","family":"Andrews","sequence":"additional","affiliation":[{"name":"Friends of Cancer Research, Washington, DC 20036, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Baehner","sequence":"additional","affiliation":[{"name":"Exact Sciences Corp., Madison, WI 53719, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Chen","sequence":"additional","affiliation":[{"name":"Tempus AI, Inc., Chicago, IL 60654, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6108-7785","authenticated-orcid":false,"given":"Carin R.","family":"Espenschied","sequence":"additional","affiliation":[{"name":"Guardant Health, Inc., Redwood City, CA 94063, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fabrizio","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, MA 02141, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Gorton","sequence":"additional","affiliation":[{"name":"Predicine, Hayward, CA 94545, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8264-0463","authenticated-orcid":false,"given":"Claire","family":"Gould","sequence":"additional","affiliation":[{"name":"Biodesix Inc., Louisville, CO 80027, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Guinney","sequence":"additional","affiliation":[{"name":"Tempus AI, Inc., Chicago, IL 60654, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9652-0294","authenticated-orcid":false,"given":"Greg","family":"Jones","sequence":"additional","affiliation":[{"name":"NeoGenomics Laboratories, Fort Myers, FL 33912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyang","family":"Lv","sequence":"additional","affiliation":[{"name":"Burning Rock, Irvine, CA 92617, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Nahorski","sequence":"additional","affiliation":[{"name":"NeoGenomics Laboratories, Fort Myers, FL 33912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie R.","family":"Palomares","sequence":"additional","affiliation":[{"name":"Exact Sciences Corp., Madison, WI 53719, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7903-2552","authenticated-orcid":false,"given":"Gary A.","family":"Pestano","sequence":"additional","affiliation":[{"name":"Biodesix Inc., Louisville, CO 80027, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2916-5269","authenticated-orcid":false,"given":"Mark","family":"Sausen","sequence":"additional","affiliation":[{"name":"Personal Genome Diagnostics, Labcorp, Baltimore, MD 21224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Silk","sequence":"additional","affiliation":[{"name":"Tempus AI, Inc., Chicago, IL 60654, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Zhang","sequence":"additional","affiliation":[{"name":"Guardant Health, Inc., Redwood City, CA 94063, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Burning Rock, Irvine, CA 92617, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Stewart","sequence":"additional","affiliation":[{"name":"Friends of Cancer Research, Washington, DC 20036, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff D.","family":"Allen","sequence":"additional","affiliation":[{"name":"Friends of Cancer Research, Washington, DC 20036, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e006013","DOI":"10.1136\/jitc-2022-006013","article-title":"Cell-free DNA approaches for cancer early detection and interception","volume":"11","author":"Medina","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e006284","DOI":"10.1136\/jitc-2022-006284","article-title":"Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA","volume":"11","author":"Semenkovich","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e005344","DOI":"10.1136\/jitc-2022-005344","article-title":"Regulatory implications of ctDNA in immuno-oncology for solid tumors","volume":"11","author":"Vellanki","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e005924","DOI":"10.1136\/jitc-2022-005924","article-title":"Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy","volume":"11","author":"Sivapalan","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e005615","DOI":"10.1136\/jitc-2022-005615","article-title":"Crucial roles of circulating tumor cells in the metastatic cascade and tumor immune escape: Biology and clinical translation","volume":"10","author":"Pantel","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e001504","DOI":"10.1136\/jitc-2020-001504","article-title":"Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)","volume":"9","author":"Ricciuti","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12967-019-2051-8","article-title":"Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy","volume":"17","author":"Seremet","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cell.2020.09.001","article-title":"Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition","volume":"183","author":"Nabet","year":"2020","journal-title":"Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e2100372","DOI":"10.1200\/PO.21.00372","article-title":"Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients with Non\u2013Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors","volume":"6","author":"Vega","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","article-title":"A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics","volume":"4","author":"Beaver","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_11","unstructured":"(2023, October 19). Use of Circulating Tumor DNA for Early-Stage Solid Tumor Drug Development Guidance for Industry DRAFT GUIDANCE, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/guidance."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e006793","DOI":"10.1136\/jitc-2023-006793","article-title":"Challenges in the implementation of ultrasensitive liquid biopsy approaches in precision oncology","volume":"11","author":"Desai","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41467-020-20162-8","article-title":"Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1158\/1078-0432.CCR-17-3837","article-title":"The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients","volume":"24","author":"Zill","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/cpt.1747","article-title":"Minimum Technical Data Elements for Liquid Biopsy Data Submitted to Public Databases","volume":"107","author":"Febbo","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00356","article-title":"Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non\u2013Small-Cell Lung Cancer Using a Decision Analytic Model","volume":"3","author":"Pennell","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/1878-0261.12729","article-title":"The effect of surgical trauma on circulating free DNA levels in cancer patients\u2014Implications for studies of circulating tumor DNA","volume":"14","author":"Henriksen","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e2300261","DOI":"10.1200\/CCI.23.00261","article-title":"The Bar Is High: Evaluating Fit-for-Use Oncology Real-World Data for Regulatory Decision Making","volume":"8","author":"Lerro","year":"2024","journal-title":"JCO Clin. Cancer Inform."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/9\/912\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:34:33Z","timestamp":1760106873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/9\/912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,27]]},"references-count":19,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["diagnostics14090912"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics14090912","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,27]]}}}